Cvs Health Corp (CVS) Stock Price & Analysis
Cvs Health Corp (CVS) fell 0.47% to USD 96.74 as of September 8, 2026 at 02:51 UTC, according to Nexqual real-time market data.
CVS last closed at USD 97.2; the session ranged USD 96.29–97.69 on volume of 4,477,395 shares. Market capitalization is $123.73B, with a 52-week range of USD 69.51–110.68 (NYQ). Source: Nexqual, September 8, 2026 at 02:51 UTC.
Key Statistics (as of September 8, 2026 at 02:51 UTC)
| Price | USD 96.74 |
|---|---|
| Change | ▼ 0.47% (down) |
| Previous Close | USD 97.2 |
| Open | USD 96.59 |
| Day Range | USD 96.29 – 97.69 |
| 52-Week Range | USD 69.51 – 110.68 |
| Volume | 4,477,395 shares |
| Market Cap | $123.73B |
| Exchange | NYQ |
Technical Analysis (CVS)
Nexqual's technical model rates CVS "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 02:51 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 44.27 (neutral) |
| vs SMA50 | Below (USD 100.79) |
| MACD | -1.09 (negative) |
Analyst Ratings (CVS)
Wall Street analysts rate CVS "Strong Buy" based on 25 analysts, with a mean price target of USD 116.04 (range USD 103–148), per Nexqual as of September 8, 2026 at 02:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 25 |
| Mean Target | USD 116.04 |
| High Target | USD 148 |
| Low Target | USD 103 |
| Buy / Hold / Sell | 24 / 3 / 0 |
Earnings (CVS)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 1.62 |
| Revenue Estimate | $104.57B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.58 vs est 1.85 ▲ beat |
| 2026-03-31 | USD 2.57 vs est 2.21 ▲ beat |
| 2025-12-31 | USD 1.09 vs est 1 ▲ beat |
| 2025-09-30 | USD 1.6 vs est 1.36 ▲ beat |
Source: Nexqual, September 8, 2026 at 02:51 UTC.
Financials & Fundamentals (CVS)
| Total Revenue | $412.64B |
|---|---|
| Revenue Growth (YoY) | +7.10% |
| Gross Margin | +13.65% |
| Operating Margin | +3.86% |
| Profit Margin | +1.18% |
| ROE | +6.21% |
| Debt / Equity | 95.5 |
| Current Ratio | 0.87 |
| Total Cash | $13.96B |
| Total Debt | $76.31B |
| Free Cash Flow | $8.08B |
Source: Nexqual, September 8, 2026 at 02:51 UTC.
Financial Health Score (CVS)
Nexqual rates Cvs Health Corp's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 02:51 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 14%, operating 4% |
| Balance Sheet | Weak — $14.0B cash vs $76.3B debt |
| Cash Flow | Mixed — FCF $8.08B, slim 2.0% margin |
| Efficiency | Mixed — ROE 6%, ROA 3.0% |
Ownership (CVS)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +90.97% |
| Shares Outstanding | 1.28B |
| Float | 1.28B |
| Short % of Float | +1.32% |
Source: Nexqual, September 8, 2026 at 02:51 UTC.
From Cvs Health Corp's Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- We serve an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan ("PDP").
- Retail Pharmacy Network Management Services The Company maintains a national network of approximately 63,000 retail pharmacies, consisting of approximately 34,500 chain pharmacies (which include CVS pharmacy locations) and approximately 28,500 independent pharmacies, in the U.S., including Puerto Rico, the District of Columbia, Guam and the U.S.
- During the year ended December 31, 2025, the Company performed more than 3.5 million IHEs. 9 While in the home, providers perform IHEs with the assistance of the Company's longitudinal patient records and proprietary clinical workflow software with its integrated device hub.
- The Health Engagement Engine ® technology and proprietary clinical algorithms help connect various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices.
Partnerships
- Under Duals contracts, the rate setting process is generally established by CMS in partnership with the state government agency participating in the demonstration project.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TGT | Target Corporation | USD 164.44 | ▲ 0.66% |
| ABBV | AbbVie Inc. | USD 256.46 | ▼ 2.01% |
| BMY | Bristol-Myers Squibb Company | USD 66.82 | ▼ 1.24% |
| UNH | UnitedHealth Group Incorporated | USD 397.14 | ▼ 0.63% |
| ABT | Abbott Laboratories | USD 108.33 | ▼ 1.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 02:51 UTC. This page is informational and not investment advice.